Professionals | Aplastic Anemia & MDS International Foundation


Hero Image

Recorded Programs

The Clinical Management of Myeloid Malignancy: The Coming Age of Targeted Therapies

Friday, December 6, 2019 | 12:00-4:00 pm
Orange County Convention Center
Orlando, FL

This Satellite Symposium, which preceded the 61st ASH Annual meeting, was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation.

The complimentary enduring program provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The program brought together leaders in disease research and clinical practice to explore solutions on improving the care of patients.

Watch program here


Riding the Wave: Clinical Management of Myeloid Malignancy in an Era of Novel Therapies

Friday, November 30, 2018 | 7:00-11:00 am
Manchester Grand Hyatt
San Diego, CA

This Satellite Symposium was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation, preceding the 60th ASH Annual Meeting.

This CME certified activity provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, PHN, AML and myeloid malignancies. This program brings together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Watch program here

Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia

Thursday, January 23, 2020 | 1:00 pm ET

At the conclusion of this program, participants will be able to:

  • Describe a management strategy for high-risk MDS/AML based on the clinical presentation, diagnostic workup and recent research findings
  • ​Explain the role of genetic testing in risk assessment and stratification for this patient population
  • Identify emerging treatment options for high-risk MDS and secondary AML
  • Discuss the roles of a multidisciplinary health care team in addressing treatment goals and providing patient education to improve outcomes, including guiding patients and caregivers in decision making, financial issues, and palliative care options
  • Identify resources for support and education for patients

Watch program here


ONS Congress Satellite Symposium

The Many Facese of Myelodysplastic Syndromes – Managing Evolving Therapies and Counseling Patients

This dinner symposium recorded at the 2019 ONS Annual Congress in Anaheim, CA focused on recent advances in diagnosing and treating myelodysplastic syndromes and related diseases, including AML and MDS/MPN overlap, and the role of nurses in disease management and care coordination. Topics include the latest developments in precision medicine for diagnosing and treating myeloid malignancies; emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap; disease management; psychosocial considerations and palliative care to improve the quality-of-life for this patient population. Case studies are used to illustrate treatment decision-making and therapeutic challenges.

Watch program here

BMT and Immunotherapies for Pediatric Leukemia: Current and Novel Treatments and Financial Implications

Sponsored jointly by the National Marrow Donor Program® / Be The Match® and the Aplastic Anemia and MDS International Foundation.

In this recorded webinar, you'll learn that bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.


  • Vicki Szenes, MS, RN, CPNP, CPHON®, Pediatric Nurse Practitioner ,
    Memorial Sloan-Kettering Cancer Center 
  • Meghan Wellenbrink, BSN, RN, CPHON, CAR-T Cell Clinical Nurse Coordinator, 
    Memorial Sloan-Kettering Cancer Center

Watch program here

MDS/MPN Overlap Disorders: The Challenges of Diagnosing and Treating

This activity is jointly provided by Medical Education Resources and the Aplastic Anemia and MDS International Foundation. Practitioners participating in this program will be able to select the most appropriate and efficacious treatment for patients with MDS/MPN from this in-depth review and analysis of recent research on the impact of molecular mutations, revised diagnostic tools, and new therapeutic options to improve outcomes.

Watch webcast here


  • David Steensma, MD, Attending Physician, Hematologic Oncology, Dana-Farber Cancer Institute
    Attending Physician, Medicine, Brigham And Women's Hospital, Associate Professor, Medicine, Harvard Medical School
  • Katherine Edmonds, ARNP, Adult Leukemia Program, Dana-Farber Cancer Institute
  • Robert Hasserjian, MD, Associate Pathologist, Massachusetts General Hospital, Associate Professor of Pathology, Harvard Medical School


The Diagnosis of Myelodysplastic Syndromes: Difficulties, Dilemmas, and Decisions

This program focuses on the latest developments in research around the pathology of MDS, and how those findings relate to clinical care of patients. Through case study examples, the speakers discuss common scenarios and potential difficulties encountered by clinicians seeking to diagnose potential MDS cases, and provide treatment and prognostic information to current patients. 

Watch webcast here


  • Vu Duong, MD, Assistant Professor of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine; 
  • Carole Miller, MD, Cancer Center Director at Ascension Health St. Agnes Cancer Center in Baltimore, MD
  • Zeba Singh, MD, Associate Professor of Pathology, University of Maryland School of Medicine



Myelodysplastic Syndromes in Older Adults: Treatment Options and Support Strategies

Sponsored jointly by the National Marrow Donor Program® / Be The Match® and the Aplastic Anemia and MDS International Foundation.

Allogeneic hematopoietic cell transplantation (HCT) is the only therapy for MDS with curative potential. Of the estimated 15,000 to 20,000 US patients diagnosed annually, >80% are >age 70 years. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy.

In this recorded continuing education webinar a physician and nurse practitioner will present current research and case examples to illustrate treatment options and common experiences for older patients with MDS and their families. The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with MDS. It is accredited for hematology/oncology nurses; hematology, oncology social workers at intermediate to advanced levels of practice, experience and licensure; and clinical laboratory professionals.

Watch program here


  • Marlise R. Luskin, MD, MSCE, Physician in Dana-Farber’s Adult Leukemia program
  • Ilene Galinsky, NP, Senior Program Research Nurse Practitioner for the Adult Leukemia Program with the Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital /BWH in Boston, Massachusetts


Treatment Decision-Making Through the Spectrum of MDS

Explaining MDS to patients can be challenging for healthcare professionals. The disease process is complex, the prognosis variable, and treatment options must be tailored for each patient. This series of three continuing education programs - one each for low risk MDS, high risk MDS, and stem cell transplantation - focuses on effective communication to ensure optimal outcomes when managing patients with MDS.

The target audience for these programs is oncologists, hematologists, oncology nurses, and other healthcare providers who diagnose and manage MDS patients.